5-Fluorouracil and Cyclophosphamide modify functional activity in submandibular gland of rats.
AbstractObjective: Chemotherapy treatment against cancer produce systemic toxicities, among which are those related to important structures of the stomatognathic system and its functional activity. 5 Fluorouracil (5-FU) and cyclophosphamide (Cf) are drugs widely used in solid tumors and in bone marrow transplantation, respectively. The objective of this work was to evaluate the toxicity of these drugs regarding functional activity of the submandibular glands, by measuring the percentage of glycogen consumption in two experimental models. Material and Methods: 84 male Wistar rats aged three months were used, housed in individual cages, with controlled temperature and lighting and ad libitum diet. They were divided into four experimental groups: 1) Control (C); 2) Treated with 5-FU+leucovorin (LV) at 20 and 10mg/Kg of body weight respectively for five consecutive days; 3) treated with Cf i.p. at 50mg/Kg of body weight for two consecutive days; and 4) rats with paired feeding (PF): for five and two days respectively, the amount administered resulted from the average of the ingested food of groups 2 and 3. Both submandibular glands were excised. The submandibular glycogen concentration was analyzed at initial time (t0) and after 60 minutes of mechanical stimulation (t60). Results: the average variation changed significantly between time 0 and 60 in the groups C and PF. (p-value=0.0001), the 5-FU + LV treatment group had an average concentration higher at t0 than groups C and PF, without significant consumption at T60. While group Cf showed a lower average concentration at time 0 with respect to groups C and PF, without significant consumption at T60. Conclusion: 5-FU+LV and Cf affect the metabolism of carbohydrates, decreasing the use of glycogen as a metabolic substrate. In the present experimental model, the toxicity of these drugs affected the functional activity of the submandibular gland.
2. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P; Meta-Analysis Group in Cancer.Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22(18):3766-75
3. Branda RF, Chen Z, Brooks EM, Naud SJ, Trainer TD, McCormack JJ. Diet modulates the toxicity of cancer chemotherapy in rats. J Lab Clin Med. 2002;140(5):358-68.
4. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M. Sargent P, Piedbois P; Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Meta-Analysis Group in Cancer. J Clin Oncol. 2004;22(18):3766-75.
5. Rojas-Morales T, Lugo Z, Santana Y, Navas R, Zambrano O, Viera N, García I. Capacidad buffer de la saliva en niños y adolescentes con cáncer: variaciones inducidas por la administración de metrotrexate o ciclofosfamida. Med Oral Patol Oral Cir Bucal.2005;10(2):E103-8.
6. Jensen SB, Pedersen AM, Reibel J, Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer.2003;11(4):207-25.
7. Nieuw Amerongen AV, Veerman EC.Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.2003;11(4):226-31.
8. Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.Ann Oncol. 2006;17(8):1205-12
9. Klaassen CD. Casarelt and Doull’s Toxicology. The Basic Science of Poisons. 8th Ed. McGraw-McGraw-Hill Education, LLC, New York. 2013. E-book conversion by codeMantra Version 2.0.
10. Joulia JM1, Pinguet F, Ychou M, Duffour J, Astre C, Bressolle F. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer. 1999;35(2):296-301.
11. Keefe DM. Mucositis management in patients with cancer. Supp Care Cancer Ther.2006;3(3):154-7.
12. Vissinik A, Burlage FR, Spijkervet FK, Veerman EC, NET Amerongen AV. Prevention and treatment of salivary gland hypofunction related to head and neck radiation therapy and chemotherapy. Support Cancer Ther.2004;1(2):111-8.
13. Mazzeo MA, Linares JA, López MM, Gallará RV, Bachmeier E, Wietz FM, Finkelberg AB. Functional impairment in submandibular gland of rats induced by 5-fluorouracil and calcium leucovorin. Acta Odontol. Latinoam.2012;25(3):262-68,
14. Jones DL, Rankin KV . Management of the oral sequelae of cancer therapy. Tex Dent J.2012;129(5):461-8.
15. Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy: are there new approaches. Cancer Nurs 27(3): 183-205, 2004
16. Nicolau J, Sassaki KT. Metabolism of carbohydrate in the major salivary glands of rats. Arch Oral Biol.1976;21(11):659-61.
17. Nicolau J, de Souza DN, Martins HR. Pilocarpine-induced increases in the activity of 6-phosphofructo-2-kinase and the fructose-2,6-bisphosphate content of rat salivary glands. Arch Oral Biol.1992;37(6):483-7.
18. Lanfri-Aguilar N, Gallará R, Linares JA, Campos L, Finkelberg A. Restricted diet modifies carbohydrate metabolism in immature rats. Prostaglandins Leukot Essent Fatty Acids. 75 (6): 351-55, 2006.
19. Jensen SB, Pedersen AM, Reibel J, Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer.2003;11(4):207-25.
20. Mazzeo MA, Linares JA, Campos ML, Busamia BE, Dubersarsky C, Lavarda M, Jarchum G, Finkelberg AB Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment. Med Oral Patol Oral Cir Bucal. 2009;14(3):E108-13.
21. Bachmeier E, Mazzeo MA, López MM, Linares JA, Jarchum G, Wietz FM, Finkelberg AB. Mucositis and salivary antioxidants in patients undergoing bone marrow transplantation (BMT). Med Oral Patol Oral Cir Bucal. 2014;19(5):e444-50.
22. Sonis ST. Oral mucositis in cancer therapy. J Support Oncol.2004;2(6 Suppl 3):3-8.
23. Ewens AD, Mihich E, Ehrke MJ. Fluorouracil plus leucovorin induces submandibular salivary gland enlargement in rats. Toxicol Pathol.2005;3:507-15.
The copyright of all the articles published in the J Oral Res. belongs to the Universidad de Concepción, Chile. All information about theJ Oral Res. is licensed under Creative Commons Attribution License 3.0 and must be cited correctly.